Patents by Inventor Jacob CHA

Jacob CHA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted amino acids as integrin inhibitors
    Patent number: 11952376
    Abstract: The invention relates to compounds of formula (I): or a salt thereof, wherein R1, G, L1, L2, L3, and Y are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are inhibitors of one, or both of, ?v?1 integrin and ?v?6 integrin that are useful for treating fibrosis such as in nonalcoholic steatohepatitis (NASH), idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).
    Type: Grant
    Filed: October 18, 2021
    Date of Patent: April 9, 2024
    Assignee: PLIANT THERAPEUTICS, INC.
    Inventors: Jacob Cha, Manuel Muñoz, Maureen Reilly, Nicole Cooper, Katerina Leftheris, David J. Morgans, Jr., Timothy Hom, Yajun Zheng, Christopher Bailey, Darren Finkelstein
  • AMINO ACID COMPOUNDS AND METHODS OF USE
    Publication number: 20240043421
    Abstract: The invention relates to compounds of formula (I): or a salt thereof, wherein R1, R5, R7, R8, X, m, n, p and q are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are ?v?6 integrin inhibitors that are useful for treating tissue specific fibrosis such as idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSW).
    Type: Application
    Filed: February 27, 2023
    Publication date: February 8, 2024
    Inventors: David John MORGANS, JR., Randall L. HALCOMB, Gustave BERGNES, Hui LI, Lan JIANG, Jacob CHA, Timothy HOM
  • Amino acid compounds with unbranched linkers and methods of use
    Patent number: 11858931
    Abstract: The invention relates to compounds of formula (A): or a salt thereof, wherein R1, R2, R5a, R5b, R6a, R6b, R7a, R7b, R8a, R8b, R9a, R9b, R10a, R10b, R11a, R11b, R21, n, and G are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are ?V?6 integrin inhibitors that are useful for treating fibrosis such as idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).
    Type: Grant
    Filed: February 23, 2022
    Date of Patent: January 2, 2024
    Assignee: PLIANT THERAPEUTICS, INC.
    Inventors: Katerina Leftheris, Maureen Reilly, Darren Finkelstein, Nicole Cooper, Christopher Bailey, Jacob Cha
  • N-ACYL AMINO ACID COMPOUNDS AND METHODS OF USE
    Publication number: 20230365556
    Abstract: The invention relates to compounds of formula (I): or a salt thereof, wherein R1, A, L, and R2 and n are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are ?v?1 integrin inhibitors that are useful for treating tissue specific fibrosis.
    Type: Application
    Filed: April 27, 2023
    Publication date: November 16, 2023
    Applicant: Pliant Therapeutics, Inc.
    Inventors: Lan JIANG, David John MORGANS, JR., Gustave BERGNES, Chun CHEN, Hui LI, Patrick ANDRE, Randall L. HALCOMB, Jacob CHA, Timothy HOM
  • AMINO ACID COMPOUNDS AND METHODS OF USE
    Publication number: 20230271960
    Abstract: The invention relates to compounds of formula (A) and formula (I): or a salt thereof, wherein R1, R2, R10, R11, R12, R13, R14, R15, R16, q and p are as described herein. Compounds of formula (A), formula (I), and pharmaceutical compositions thereof are ?v?6 integrin inhibitors that are useful for treating fibrosis such as idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).
    Type: Application
    Filed: December 19, 2022
    Publication date: August 31, 2023
    Inventors: Jacob CHA, Chengguo DONG, Timothy HOM, Lan JIANG, Katerina LEFTHERIS, Hui LI, Manuel MUNOZ, David John MORGANS, JR., Maureen REILLY, Yajun ZHENG, Christopher BAILEY, Darren FINKELSTEIN
  • TREATMENT OF RESPIRATORY DISEASES WITH AMINO ACID COMPOUNDS
    Publication number: 20230181546
    Abstract: The invention relates to methods of therapy using compounds of formula (I) and formula (II): or a salt thereof, wherein R1, R2, R10, R11, R12, R13, R14, R15, R16, q and p are as described herein. Compounds of formula (II) and pharmaceutical compositions thereof are integrin inhibitors that are useful in therapy for a condition, for example, caused by or associated with an infectious agent, shock, pancreatitis, or trauma. The condition can include one or more of pulmonary fibrosis associated with rheumatoid arthritis or progressive familial intrahepatic cholestasis (PFIC).
    Type: Application
    Filed: April 30, 2021
    Publication date: June 15, 2023
    Inventors: Eric LEFEBVRE, Scott TURNER, Jacob CHA, Chengguo DONG, Timothy HOM, Lan JIANG, Katerina LEFTHERIS, Hui LI, David J. MORGANS, Jr., Manuel MUNOZ, Maureen REILLY, Yajun ZHENG, Kraig ANDERSON
  • N-acyl amino acid compounds and methods of use
    Patent number: 11673887
    Abstract: The invention relates to compounds of formula (I): or a salt thereof, wherein R1, A, L, and R2 and n are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are ?v?1 integrin inhibitors that are useful for treating tissue specific fibrosis.
    Type: Grant
    Filed: March 4, 2020
    Date of Patent: June 13, 2023
    Assignee: Pliant Therapeutics, Inc.
    Inventors: Lan Jiang, David John Morgans, Jr., Gustave Bergnes, Chun Chen, Hui Li, Patrick Andre, Randall Halcomb, Jacob Cha, Timothy Hom
  • Amino acid compounds and methods of use
    Patent number: 11634418
    Abstract: The invention relates to compounds of formula (I): or a salt thereof, wherein R1, R5, R7, R8, X, m, n, p and q are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are ?v?6 integrin inhibitors that are useful for treating tissue specific fibrosis such as idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).
    Type: Grant
    Filed: June 5, 2020
    Date of Patent: April 25, 2023
    Assignee: Pliant Therapeutics, Inc.
    Inventors: David John Morgans, Jr., Randall L. Halcomb, Gustave Bergnes, Hui Li, Lan Jiang, Jacob Cha, Timothy Hom
  • COMBINATION TREATMENT OF LIVER DISEASES USING INTEGRIN INHIBITORS
    Publication number: 20230060422
    Abstract: The invention provides a pharmaceutical combination including an ?v?1 integrin inhibitor and at least one additional therapeutic agent for preventing, delaying or treating liver diseases or disorders. The additional therapeutic agent may be an SGLT1/2 inhibitor, among a diverse selection of agents. For example, the pharmaceutical combination includes (S)-2-(4-methyltetrahydro-2H-pyran-4-carboxamido)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl) nonanoic acid (Compound 1) and at least one additional therapeutic agent.
    Type: Application
    Filed: December 18, 2020
    Publication date: March 2, 2023
    Inventors: Kraig ANDERSON, Christopher BAILEY, Avirup BOSE, Jacob CHA, Nicole COOPER, Darren FINKELSTEIN, Linda GREENBAUM, Johannes HULL, Susan Caroline KIRKLAND, Katerina LEFTHERIS, Maureen REILLY, Peter TARSA, Chinweike UKOMADU
  • COMBINATION TREATMENT OF LIVER DISEASES USING INTEGRIN INHIBITORS
    Publication number: 20230055657
    Abstract: The invention provides a pharmaceutical combination including an ?v?1 integrin inhibitor and at least one additional therapeutic agent for preventing, delaying or treating liver diseases or disorders. The at least one additional therapeutic agent may be a farnesoid X receptor (FXR) agonist. For example, the pharmaceutical combination includes (S)-2-(4-methyltetrahydro-2H-pyran-4-carboxamido)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid (Compound 1) and 2-[3-({5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl}methoxy)-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1, 3-ben-zothiazole-6-carboxylic acid (tropifexor).
    Type: Application
    Filed: December 18, 2020
    Publication date: February 23, 2023
    Inventors: Kraig ANDERSON, Christopher BAILEY, Avirup BOSE, Jacob CHA, Nicole COOPER, Darren FINKELSTEIN, Linda GREENBAUM, Johannes HULL, Susan Caroline KIRKLAND, Katerina LEFTHERIS, Maureen REILLY, Peter TARSA, Chinweike UKOMADU
  • Amino acid compounds and methods of use
    Patent number: 11560376
    Abstract: The invention relates to compounds of formula (A) and formula (I): or a salt thereof, wherein R1, R2, R10, R11, R12, R13, R14, R15, R16, q and p are as described herein. Compounds of formula (A), formula (I), and pharmaceutical compositions thereof are ?v?6 integrin inhibitors that are useful for treating fibrosis such as idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).
    Type: Grant
    Filed: June 26, 2020
    Date of Patent: January 24, 2023
    Assignee: Pliant Therapeutics, Inc.
    Inventors: Jacob Cha, Chengguo Dong, Timothy Hom, Lan Jiang, Katerina Leftheris, Hui Li, David John Morgans, Jr., Manuel Munoz, Maureen Reilly, Yajun Zheng, Christopher Bailey, Darren Finklestein
  • AMINO ACID COMPOUNDS WITH UNBRANCHED LINKERS AND METHODS OF USE
    Publication number: 20220289743
    Abstract: The invention relates to compounds of formula (A): or a salt thereof, wherein R1, R2, R5a, R5b, R6a, R6b, R7a, R7b, R8a, R8b, R9a, R9b, R10a, R10b, R11a, R11b, R21, n, and G are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are ?v?6 integrin inhibitors that are useful for treating fibrosis such as idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).
    Type: Application
    Filed: February 23, 2022
    Publication date: September 15, 2022
    Inventors: Katerina LEFTHERIS, Maureen REILLY, Darren FINKELSTEIN, Nicole COOPER, Christopher BAILEY, Jacob CHA
  • Amino acid compounds with unbranched linkers and methods of use
    Patent number: 11396506
    Abstract: The invention relates to compounds of formula (A): or a salt thereof, wherein R1, R2, R5a, R5b, R6a, R6b, R7a, R7b, R8a, R8b, R9a, R9b, R10a, R10b, R11a, R11b, R21, n, and G are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are ?V?6 integrin inhibitors that are useful for treating fibrosis such as idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).
    Type: Grant
    Filed: June 27, 2019
    Date of Patent: July 26, 2022
    Assignee: Pliant Therapeutics, Inc.
    Inventors: Katerina Leftheris, Maureen Reilly, Darren Finkelstein, Nicole Cooper, Christopher Bailey, Jacob Cha
  • INTEGRIN INHIBITOR AND USES THEREOF
    Publication number: 20220177468
    Abstract: Provided herein are integrin inhibitors, compositions thereof, and methods of their uses. Crystalline forms of salts of the inhibitors are also described, along with methods of preparing the crystalline forms. X-ray powder diffraction data, thermogravimetric analysis, and differential scanning calorimetry data are provided for the crystalline forms. The integrin inhibitors are useful for treatment of, inter alia, fibrotic diseases.
    Type: Application
    Filed: November 19, 2021
    Publication date: June 9, 2022
    Inventors: Jacob CHA, Katerina LEFTHERIS, Qi GAO, Jian WANG, Dalian ZHAO
  • AMINO ACID COMPOUNDS AND METHODS OF USE
    Publication number: 20220144829
    Abstract: The invention relates to compounds of formula (I): or a salt thereof, wherein R1, G, L1, L2, L3, and Y are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are inhibitors of one, or both of, ?v?1 integrin and ?v?6 integrin that are useful for treating fibrosis such as in nonalcoholic steatohepatitis (NASH), idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).
    Type: Application
    Filed: October 18, 2021
    Publication date: May 12, 2022
    Inventors: Jacob CHA, Manuel MUÑOZ, Maureen REILLY, Nicole COOPER, Katerina LEFTHERIS, David J. MORGANS, JR., Timothy HOM, Yajun ZHENG
  • Substituted amino acids as integrin inhibitors
    Patent number: 11180494
    Abstract: The invention relates to compounds of formula (I): or a salt thereof, wherein R1, G, L1, L2, L3, and Y are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are inhibitors of one, or both of, ?v?1 integrin and ?v?6 integrin that are useful for treating fibrosis such as in nonalcoholic steatohepatitis (NASH), idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).
    Type: Grant
    Filed: October 8, 2019
    Date of Patent: November 23, 2021
    Assignee: Pliant Therapeutics, Inc.
    Inventors: Jacob Cha, Manuel Munoz, Maureen Reilly, Nicole Cooper, Katerina Leftheris, David J. Morgans, Jr., Timothy Hom, Yajun Zheng
  • AMINO ACID COMPOUNDS AND METHODS OF USE
    Publication number: 20210122747
    Abstract: The invention relates to compounds of formula (I): or a salt thereof, wherein R1, R5, R7, R8. X, m, n, p and q are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are ?v?6 integrin inhibitors that are useful for treating tissue specific fibrosis such as idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).
    Type: Application
    Filed: June 5, 2020
    Publication date: April 29, 2021
    Inventors: David John MORGANS, Jr., Randall L. HALCOMB, Gustave BERGNES, Hui LI, Lan JIANG, Jacob CHA, Timothy HOM
  • N-ACYL AMINO ACID COMPOUNDS AND METHODS OF USE
    Publication number: 20210024516
    Abstract: The invention relates to compounds of formula (I): or a salt thereof, wherein R1, A, L, and R2 and n are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are ?v?1 integrin inhibitors that are useful for treating tissue specific fibrosis.
    Type: Application
    Filed: March 4, 2020
    Publication date: January 28, 2021
    Inventors: Lan JIANG, David John MORGANS, Jr., Gustave BERGNES, Chun CHEN, Hui LI, Patrick ANDRE, Randall HALCOMB, Jacob CHA, Timothy HOM
  • AMINO ACID COMPOUNDS AND METHODS OF USE
    Publication number: 20210017171
    Abstract: The invention relates to compounds of formula (A) and formula (I): or a salt thereof, wherein R1, R2, R10, R11, R12, R13, R14, R15, R16, q and p are as described herein. Compounds of formula (A), formula (I), and pharmaceutical compositions thereof are ?v?6 integrin inhibitors that are useful for treating fibrosis such as idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).
    Type: Application
    Filed: June 26, 2020
    Publication date: January 21, 2021
    Inventors: Jacob CHA, Chengguo DONG, Timothy HOM, Lan JIANG, Katerina LEFTHERIS, Hui LI, David John MORGANS, JR., Manuel MUNOZ, Maureen REILLY, Yajun ZHENG
  • DOSAGE FORMS AND REGIMENS FOR AMINO ACID COMPOUNDS
    Publication number: 20200352942
    Abstract: The invention relates to dosage forms for daily administration of compounds of formula (A) and formula (I): or a salt thereof, wherein R1, R2, R10, R11, R12, R13, R14, R15, R16, q and p are as described herein. Compounds of formula (A), formula (I), and pharmaceutical compositions thereof are ?v?6 integrin inhibitors that are useful for treating fibrosis such as idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).
    Type: Application
    Filed: April 8, 2020
    Publication date: November 12, 2020
    Inventors: Jacob CHA, Chengguo DONG, Timothy HOM, Lan JIANG, Katerina LEFTHERIS, Hui LI, David J. MORGANS, JR., Manuel MUNOZ, Maureen REILLY, Yajun ZHENG, Martin DECARIS, Scott TURNER